drugset

drugset / Trial / NCT02189577

Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients

NCT02189577 ↗

Phase 2 Completed 100 enrolled Chiesi Farmaceutici S.p.A.

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of CHF 5259 (glycopyrrolate bromide) for the treatment of COPD patients.

Timeline

Start: 2014-06
Primary completion: 2015-02
Completion: 2015-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glycopyrrolate	Small molecule	—	Inhaled

Indications